Jasper Therapeutics, Inc. financial data

Symbol
JSPR, JSPRW on Nasdaq
Location
Redwood City, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 328% % -65%
Debt-to-equity 74% % 373%
Return On Equity -262% % -641%
Return On Assets -151% % -393%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27,984,039 shares
Common Stock, Shares, Outstanding 27,984,039 shares 87%
Entity Public Float $281,000,000 USD 154%
Common Stock, Value, Issued $3,000 USD 50%
Weighted Average Number of Shares Outstanding, Basic 16,635,784 shares 11%
Weighted Average Number of Shares Outstanding, Diluted 16,635,784 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue $9,345,000 USD 6.4%
Research and Development Expense $71,516,000 USD 43%
General and Administrative Expense $21,813,000 USD 16%
Operating Income (Loss) $93,329,000 USD -36%
Nonoperating Income (Expense) $2,308,000 USD -55%
Net Income (Loss) Attributable to Parent $91,021,000 USD -174%
Earnings Per Share, Basic -5 USD/shares -259%
Earnings Per Share, Diluted -5 USD/shares -259%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $50,899,000 USD -45%
Other Assets, Current $863,000 USD 38%
Assets, Current $54,564,000 USD -42%
Property, Plant and Equipment, Net $1,102,000 USD -47%
Operating Lease, Right-of-Use Asset $1,236,000 USD 12%
Other Assets, Noncurrent $150,000 USD -85%
Assets $57,469,000 USD -42%
Accounts Payable, Current $9,166,000 USD 197%
Employee-related Liabilities, Current $1,657,000 USD -36%
Liabilities, Current $21,041,000 USD 69%
Operating Lease, Liability, Noncurrent $201,000 USD -84%
Other Liabilities, Noncurrent $2,264,000 USD 0%
Liabilities $45,898,000 USD 192%
Retained Earnings (Accumulated Deficit) $307,569,000 USD -42%
Stockholders' Equity Attributable to Parent $11,571,000 USD -86%
Liabilities and Equity $57,469,000 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $22,842,000 USD -45%
Net Cash Provided by (Used in) Financing Activities $47,349,000 USD -53%
Net Cash Provided by (Used in) Investing Activities $4,000 USD
Common Stock, Shares Authorized 492,000,000 shares 0%
Common Stock, Shares, Issued 27,984,039 shares 87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $51,316,000 USD -45%
Deferred Tax Assets, Gross $61,824,000 USD 32%
Operating Lease, Liability $1,703,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid $1,758,000 USD -21%
Property, Plant and Equipment, Gross $5,007,000 USD -12%
Operating Lease, Liability, Current $1,703,000 USD 61%
Lessee, Operating Lease, Liability, to be Paid, Year Two $740,000 USD -38%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,260,000 USD 6.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $55,000 USD -64%
Deferred Tax Assets, Operating Loss Carryforwards $31,820,000 USD 27%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,059,000 USD 26%
Operating Lease, Payments $356,000 USD 25%
Additional Paid in Capital $319,137,000 USD 6.3%
Deferred Tax Assets, Net of Valuation Allowance $234,000 USD -52%
Share-based Payment Arrangement, Expense $7,022,000 USD 21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%